Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/20/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. ACN
9. AZN
10. SPCX

Go back to Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel
(NASDAQ: LABT) Delayed: 1.99 +0.13 (6.99%)
Previous Close $1.86    52 Week High $ 
Open $1.92    52 Week Low $ 
Day High $2.15    P/E N/A 
Day Low $1.89    EPS $ 
Volume 287,863